COMP <GO>
COLL vs MRK // GROSS PROFIT MARGIN
Collegium Pharmaceutical Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: COLL 4
— MRK 7
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $23.80 (-0.96%) • MKT CAP: $774.8M
gross-margins
59.30%
LAST: $149.52 (+2.18%) • MKT CAP: $368.89B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 59.30% | 74.80% | -15.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 20.70% | +64.30 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 15.3x | -12.30 | COLL | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | 34.30% | -11.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 28.10% | -20.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 1.30% | +22.30 | COLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 5.19 | -3.92 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 56.3 | -0.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | 18.4x | -8.00 | COLL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $774.8M | $368.89B | -$368.12B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | MRK REV | COLL GROSS % | MRK GROSS % | COLL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $65.01B | 59.3% | 74.8% | $327.6M | $12.36B |
| FY 2024 | $631.4M | $64.17B | 59.8% | 76.3% | $203.3M | $18.10B |
| FY 2023 | $566.8M | $60.12B | — | — | $274.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
MRK // BETA 0.92